US Stock MarketDetailed Quotes
IRWD Ironwood Pharmaceuticals
- 3.340
- -0.180-5.11%
Close Nov 21 16:00 ET
534.49MMarket Cap-334000P/E (TTM)
3.740High3.310Low2.57MVolume3.530Open3.520Pre Close8.65MTurnover2.07%Turnover RatioLossP/E (Static)160.03MShares15.70052wk High-1.72P/B414.01MFloat Cap3.31052wk Low--Dividend TTM123.96MShs Float21.200Historical High--Div YieldTTM12.22%Amplitude3.310Historical Low3.368Avg Price1Lot Size
Ironwood Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -19.47%91.59M | -12.09%94.4M | -28.05%74.88M | 7.83%442.74M | 9.66%117.55M | 4.70%113.74M | 10.44%107.38M | 6.70%104.06M | -0.76%410.6M | -8.48%107.2M |
| Operating revenue | -19.47%91.59M | -12.09%94.4M | -28.05%74.88M | 7.83%442.74M | 9.66%117.55M | 4.70%113.74M | 10.44%107.38M | 6.70%104.06M | -0.76%410.6M | -8.48%107.2M |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | -4.48%65.94M | -22.64%67.35M | 44.25%63.42M | 71.22%274.4M | 91.43%74.34M | 71.87%69.03M | 109.40%87.06M | 10.79%43.96M | -11.72%160.26M | -35.85%38.84M |
| Selling and administrative expenses | 0.19%36.11M | -29.57%36.96M | 20.85%37.61M | 36.48%158.31M | 36.20%38.67M | 25.95%36.05M | 74.23%52.48M | 7.82%31.12M | 4.37%115.99M | -1.04%28.39M |
| Research and development costs | -9.57%29.83M | -12.11%30.39M | 100.94%25.82M | 162.25%116.09M | 241.53%35.68M | 185.71%32.99M | 201.93%34.58M | 18.71%12.85M | -37.13%44.27M | -67.20%10.45M |
| Operating profit | -42.62%25.65M | 33.08%27.04M | -80.94%11.46M | -32.76%168.34M | -36.79%43.21M | -34.71%44.71M | -63.49%20.32M | 3.89%60.1M | 7.80%250.34M | 20.80%68.36M |
| Net non-operating interest income expense | -2.18%-8.27M | -188.20%-6.1M | -205.52%-6.06M | -239.67%-2.66M | -284.41%-7.23M | -730.63%-8.09M | 681.75%6.92M | 372.15%5.75M | 106.25%1.9M | 150.44%3.92M |
| Non-operating interest income | -34.10%1.15M | -84.37%1.37M | -83.92%1.17M | 99.67%18.97M | -78.08%1.19M | -37.73%1.75M | 760.22%8.76M | 3,061.74%7.27M | 1,208.68%9.5M | 2,925.56%5.45M |
| Non-operating interest expense | -4.27%9.42M | 305.98%7.47M | 506.49%6.82M | 184.67%21.63M | 182.75%8.42M | 774.58%9.84M | 8.81%1.84M | -37.64%1.13M | -75.61%7.6M | -67.58%2.98M |
| Total other finance cost | ---- | ---- | 1.49%408K | ---- | ---- | ---- | ---- | -25.14%402K | ---- | ---- |
| Other net income (expense) | 99.66%-16K | 99.81%-2.07M | -2,400.00%-437K | -612,048.90%-1.11B | -31,127.78%-5.62M | -3,202.65%-4.69M | -161,935.24%-1.1B | -97.40%19K | 116.05%182K | 99.30%-18K |
| Gain on sale of security | ---- | ---- | ---- | -89.56%19K | --0 | ---- | ---- | -97.40%19K | 115.45%182K | 99.30%-18K |
| Special income (charges) | 99.66%-16K | 99.81%-2.07M | ---437K | ---1.11B | ---5.62M | ---4.69M | ---1.1B | --0 | --0 | --0 |
| -Less：Restructuring and merger&acquisition | -99.66%16K | -84.11%2.07M | --437K | --18.32M | --621K | --4.69M | --13.01M | --0 | --0 | --0 |
| -Less:Other special charges | ---- | ---- | ---- | --1.1B | --5M | ---- | --1.09B | ---- | ---- | ---- |
| Income before tax | -45.61%17.37M | 101.75%18.88M | -92.47%4.96M | -475.59%-948.07M | -57.99%30.36M | -54.32%31.93M | -2,100.97%-1.08B | 16.64%65.86M | 25.80%252.42M | 56.23%72.27M |
| Income tax | -23.68%13.72M | 48.88%19.74M | -54.73%9.12M | 7.93%83.49M | 37.21%32.11M | -8.21%17.98M | -20.65%13.26M | 14.06%20.15M | 123.60%77.36M | 379.37%23.4M |
| Net income | -73.86%3.65M | 99.92%-860K | -109.10%-4.16M | -689.24%-1.03B | -103.57%-1.75M | -72.28%13.95M | -3,038.18%-1.09B | 17.82%45.71M | -66.87%175.07M | 18.11%48.87M |
| Net income continuous Operations | -73.86%3.65M | 99.92%-860K | -109.10%-4.16M | -689.24%-1.03B | -103.57%-1.75M | -72.28%13.95M | -3,038.18%-1.09B | 17.82%45.71M | -66.87%175.07M | 18.11%48.87M |
| Minority interest income | 0 | 0 | -29.32M | -658K | -1.37M | -27.29M | 0 | 0 | ||
| Net income attributable to the parent company | -76.20%3.65M | 99.92%-860K | -109.10%-4.16M | -672.50%-1B | -102.22%-1.09M | -69.55%15.32M | -2,964.58%-1.06B | 17.82%45.71M | -66.87%175.07M | 18.11%48.87M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -76.20%3.65M | 99.92%-860K | -109.10%-4.16M | -672.50%-1B | -102.22%-1.09M | -69.55%15.32M | -2,964.58%-1.06B | 17.82%45.71M | -66.87%175.07M | 18.11%48.87M |
| Basic earnings per share | -80.00%0.02 | 99.85%-0.01 | -110.00%-0.03 | -670.80%-6.45 | -103.13%-0.01 | -69.70%0.1 | -2,950.00%-6.84 | 20.00%0.3 | -65.34%1.13 | 28.00%0.32 |
| Diluted earnings per share | -77.78%0.02 | 99.85%-0.01 | -112.00%-0.03 | -771.88%-6.45 | -103.70%-0.01 | -67.86%0.09 | -3,357.14%-6.84 | 19.05%0.25 | -70.09%0.96 | 8.00%0.27 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data